Eli Lilly made its presence known at the European Hematology Association meeting over the weekend. The drugmaker showcased first-ever data from its acquisition of Ajax Therapeutics and padded its case for Jaypirca's combination use in relapsed chronic lymphocytic leukemia. Ayisha Sharma has the details.